Abstract
In this study we examined whether treatment with 1,25-dihydroxyvitaminD3 (1,25(OH)2D3) affects human APC maturation in vitro under multiple cytokine milieus. Human monocytes were elutriated from whole blood, incubated with human sera in the presence or absence of 1,25(OH)2D3, and stimulated with IFNα, GM-CSF/IL-4, or were cultured without stimulatory cytokines. Incubation of control monocytes with 1,25(OH)2D3 limited expression of cell surface makers of maturation whether monocytes were stimulated in IFNα, GM-CSF/IL-4, or in serum alone. The ability of 1,25(OH)2D3 to affect human monocyte phenotype was assessed by incubating cells with sera from 15 patients with SLE and from 5 healthy volunteers. Addition of 1,25(OH)2D3 resulted in significant reductions in the expression of MHC Class II, CD40, and CD86 and increases in expression of CD14 in both types of sera. Overall, 1,25(OH)2D3 limited human APC activation via IFNα-induced and independent mechanisms. 1,25(OH)2D3 inhibited APC activation by systemic lupus erythematosus (SLE) sera, suggesting that it may be possible for 1,25(OH)2D3 to reduce the immunostimulatory effects of the SLE milieu by interfering with the soluble cytokine mediators in the sera of SLE patients.
Get full access to this article
View all access options for this article.
